Legend Biotech Corp
9LB
Company Profile
Business description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact
2101 Cottontail Lane
SomersetNJ08873
USAT: +1 737 317-5050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,800
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
stocks
The largest share trading on the ASX remains materially overvalued
Profit barely budges on the most expensive bank in the world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,118.00 | 0.60 | 0.01% |
| CAC 40 | 8,156.23 | 0.00 | 0.00% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,927.96 | 559.33 | 1.18% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,912.52 | 216.11 | 0.81% |
| NASDAQ | 23,468.30 | 58.87 | -0.25% |
| Nikkei 225 | 50,927.29 | 84.36 | 0.17% |
| NZX 50 Index | 13,678.86 | 74.31 | 0.55% |
| S&P 500 | 6,846.61 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,837.30 | 1.30 | 0.01% |
| SSE Composite Index | 4,004.86 | 2.10 | 0.05% |